Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer

Inclusion Criteria:

- The subject must be ≥ 18 years old on the day of consent.

- The subject is able to understand written and spoken English.

- The patient must have histologically or cytologically confirmed prostate
adenocarcinoma.

- The subject must have castration-resistant prostate cancer (CRPC).

- The subject must have metastatic disease involving bone, seen on radiographic imaging
(bone scan, CT scan, PET scan, or MRI).

- The subject must be in a castrate state (e.g., currently receiving androgen
deprivation therapy or have had an orchiectomy).

- The subject must be starting any line of systemic treatment post-androgen
deprivation/antiandrogen therapy, with any of the following: chemotherapy (e.g.,
docetaxel, paclitaxel, carboplatin, cabazitaxel, or mitoxantrone); abiraterone
acetate; MDV3100; ketoconazole; a clinical trial.

- The subject owns or has regular access to a telephone (cellular or land line).

- The subject is willing and able to self-report pain and analgesic use via an
automated telephone system.

- The subject is willing and able to provide informed consent.

Exclusion Criteria:

- The subject has small cell or predominantly neuroendocrine differentiated prostate
tumor.